194 related articles for article (PubMed ID: 24335682)
1. Prostate cancer, version 1.2014.
Mohler JL; Kantoff PW; Armstrong AJ; Bahnson RR; Cohen M; D'Amico AV; Eastham JA; Enke CA; Farrington TA; Higano CS; Horwitz EM; Kawachi MH; Kuettel M; Lee RJ; Macvicar GR; Malcolm AW; Miller D; Plimack ER; Pow-Sang JM; Richey S; Roach M; Rohren E; Rosenfeld S; Small EJ; Srinivas S; Stein C; Strope SA; Tward J; Walsh PC; Shead DA; Ho M;
J Natl Compr Canc Netw; 2013 Dec; 11(12):1471-9. PubMed ID: 24335682
[TBL] [Abstract][Full Text] [Related]
2. New developments in the management of prostate cancer.
Kantoff PW; Mohler JL
J Natl Compr Canc Netw; 2013 May; 11(5 Suppl):653-7. PubMed ID: 23704236
[TBL] [Abstract][Full Text] [Related]
3. Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial.
Saad F; Carles J; Gillessen S; Heidenreich A; Heinrich D; Gratt J; Lévy J; Miller K; Nilsson S; Petrenciuc O; Tucci M; Wirth M; Federhofer J; O'Sullivan JM;
Lancet Oncol; 2016 Sep; 17(9):1306-16. PubMed ID: 27473888
[TBL] [Abstract][Full Text] [Related]
4. Radium-223 dichloride for metastatic castration-resistant prostate cancer: the urologist's perspective.
Shore ND
Urology; 2015 Apr; 85(4):717-24. PubMed ID: 25681834
[TBL] [Abstract][Full Text] [Related]
5. Prostate cancer, Version 3.2012: featured updates to the NCCN guidelines.
Mohler JL; Armstrong AJ; Bahnson RR; Boston B; Busby JE; D'Amico AV; Eastham JA; Enke CA; Farrington T; Higano CS; Horwitz EM; Kantoff PW; Kawachi MH; Kuettel M; Lee RJ; MacVicar GR; Malcolm AW; Miller D; Plimack ER; Pow-Sang JM; Roach M; Rohren E; Rosenfeld S; Srinivas S; Strope SA; Tward J; Twardowski P; Walsh PC; Ho M; Shead DA
J Natl Compr Canc Netw; 2012 Sep; 10(9):1081-7. PubMed ID: 22956807
[TBL] [Abstract][Full Text] [Related]
6. Radium-223 dichloride: a novel treatment option for castration-resistant prostate cancer patients with symptomatic bone metastases.
McGann S; Horton ER
Ann Pharmacother; 2015 Apr; 49(4):469-76. PubMed ID: 25573268
[TBL] [Abstract][Full Text] [Related]
7. Radium-223 dichloride for the treatment of metastatic prostate cancer.
Turner PG; O'Sullivan J
Expert Opin Pharmacother; 2014 Oct; 15(14):2105-11. PubMed ID: 25186336
[TBL] [Abstract][Full Text] [Related]
8. New developments in metastatic prostate cancer therapy.
Manickavasagar T; Gilson C; Chowdhury S; Kirby R
Practitioner; 2015 Apr; 259(1781):21-4, 2-3. PubMed ID: 26529826
[TBL] [Abstract][Full Text] [Related]
9. Radium-223 for primary bone metastases in patients with hormone-sensitive prostate cancer after radical prostatectomy.
Wenter V; Herlemann A; Fendler WP; Ilhan H; Tirichter N; Bartenstein P; Stief CG; la Fougère C; Albert NL; Rominger A; Gratzke C
Oncotarget; 2017 Jul; 8(27):44131-44140. PubMed ID: 28484088
[TBL] [Abstract][Full Text] [Related]
10. FDA approves radiopharmaceutical for metastatic prostate cancer.
Cancer Discov; 2013 Jul; 3(7):OF1. PubMed ID: 23847352
[TBL] [Abstract][Full Text] [Related]
11. Radium-223 dichloride in clinical practice: a review.
Florimonte L; Dellavedova L; Maffioli LS
Eur J Nucl Med Mol Imaging; 2016 Sep; 43(10):1896-909. PubMed ID: 27121689
[TBL] [Abstract][Full Text] [Related]
12. Three-year follow-up of a phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer and bone metastases.
Uemura H; Uemura H; Nagamori S; Wakumoto Y; Kimura G; Kikukawa H; Yokomizo A; Mizokami A; Kosaka T; Masumori N; Kawasaki Y; Yonese J; Nasu Y; Fukasawa S; Sugiyama T; Kinuya S; Hosono M; Yamaguchi I; Akagawa T; Matsubara N
Int J Clin Oncol; 2019 May; 24(5):557-566. PubMed ID: 30875000
[TBL] [Abstract][Full Text] [Related]
13. Radium-223 dichloride: a new paradigm in the treatment of prostate cancer.
Anido Herranz U; Fernández Calvo O; Afonso Afonso FJ; Rodríguez Martínez de Llano S; Lázaro Quintela M; León Mateos L; Vázquez Estévez S; Antón Aparicio LM
Expert Rev Anticancer Ther; 2015 Mar; 15(3):339-48. PubMed ID: 25555355
[TBL] [Abstract][Full Text] [Related]
14. [Bone-specific therapy with radium-223 dichloride : Castration-resistant prostate cancer with symptomatic bone metastases].
Tauber R; Gschwend J; Scheidhauer K; Eiber M; Krönke M
Urologe A; 2017 Jan; 56(1):24-31. PubMed ID: 28058455
[TBL] [Abstract][Full Text] [Related]
15. NCCN Guidelines Updates: Management of Prostate Cancer.
Mohler JL; Antonarakis ES
J Natl Compr Canc Netw; 2019 May; 17(5.5):583-586. PubMed ID: 31117038
[TBL] [Abstract][Full Text] [Related]
16. Radium-223 Therapy of Bone Metastases in Prostate Cancer.
Nilsson S
Semin Nucl Med; 2016 Nov; 46(6):544-556. PubMed ID: 27825434
[TBL] [Abstract][Full Text] [Related]
17. Metabolism and pharmacokinetics of radium-223 in prostate cancer.
Yeku O; Slovin SF
Expert Opin Drug Metab Toxicol; 2015 May; 11(5):843-9. PubMed ID: 25740232
[TBL] [Abstract][Full Text] [Related]
18. Bone Health and Bone-targeted Therapies for Prostate Cancer: a Programme in Evidence-based Care - Cancer Care Ontario Clinical Practice Guideline.
Alibhai SMH; Zukotynski K; Walker-Dilks C; Emmenegger U; Finelli A; Morgan SC; Hotte SJ; Winquist E;
Clin Oncol (R Coll Radiol); 2017 Jun; 29(6):348-355. PubMed ID: 28169118
[TBL] [Abstract][Full Text] [Related]
19. Radium Ra 223 dichloride in castration-resistant prostate cancer.
Joung JY; Ha YS; Kim IY
Drugs Today (Barc); 2013 Aug; 49(8):483-90. PubMed ID: 23977665
[TBL] [Abstract][Full Text] [Related]
20. Treatment landscape of metastatic prostate cancer: the role of radium-223.
Dermine A; Machiels JP
Acta Clin Belg; 2017 Feb; 72(1):19-23. PubMed ID: 27377415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
